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Open access under the ElThe control of viral infections, mainly those caused by inﬂuenza viruses, is of great interest in Public
Health. Several studies have shown the presence of active properties in the hemolymph of arthropods,
some of which are of interest for the development of new pharmacological drugs. Recently, we have dem-
onstrated the existence of a potent antiviral property in the hemolymph of Lonomia obliqua caterpillars.
The aim of this study was to produce an antiviral protein in a baculovirus/Sf9 cell system. The resulting
bacmid contains the sequence coding for the antiviral protein previously described by our group. Total
RNA from L. obliqua caterpillars was extracted with Trizol and used in the reverse transcription assay with
oligo(d)T primer followed by polymerase chain reactions (RT-PCR) with speciﬁc primers for the cDNA
coding for the antiviral protein, based on the sequence deposited in the GenBank database. Restriction
sites were inserted in the cDNA for ligation in the donor plasmid pFastBac1™. The recombinant plasmid
was selected in Escherichia coli DH5a and subsequently used in the transformation of E. coli DH10Bac for
the construction of the recombinant bacmid. This bacmid was used for the expression of the antiviral pro-
tein in the baculovirus/Sf9 cell system. After identifying the protein by western blot, activity tests were
performed, showing that the puriﬁed recombinant protein was able to signiﬁcantly reduce viral replica-
tion (about 4 logs). Studies on the optimization of the expression system for the production of this anti-
viral protein in insect cells are in progress.
 2011 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
The ﬁrst licensed human therapeutic protein using the recombi-
nant DNA technology was insulin, produced in 1982 on a large
scale in Escherichia coli. However, due to the impossibility to
express complex proteins with post-translational modiﬁcations
in bacteria, animal cells have become a more attractive alternative
for industrial purposes (Butler, 2005). Animal cell cultures were
developed in the last decade of the 19th century with the ﬁrst
attempts to hold pieces of fabric in plasma or biological ﬂuids for
several days or weeks. Since then, Technology of Animal Cell
Cultures has achieved great progress, and is currently one of the
most successful tools in biotechnology (Kretzmer, 2002).arasitologia, Instituto Butan-
SP, Brazil. Tel.: +55 11 3726
butantan.gov.br (R.Z. Mendo-
sevier OA license. Animal cell cultures require a complex medium, often supple-
mented with expensive bovine serum which provides essential
proteins, such as growth factors, that have to be removed during
downstream processing (Reyes-Ruiz and Barrera-Saldana, 2006).
An attractive alternative is the use of the expression in the baculo-
virus/insect cell system described by Smith et al. (1983). This
system is widely used as a tool for the production of recombinant
proteins that require complex post-translational modiﬁcations
(Carpentier et al., 2001). Glycosylation, which is the addition of
carbohydrates (glycans) to proteins synthesized by animal cells,
is one of the examples of post-translational modiﬁcation. The
parameters of cell culture – such as nutrients, oxygen, toxic metab-
olites, concentration, pH and temperature – may have signiﬁcant
effects on the glycan structure distribution in recombinant
proteins, and therefore require efﬁcient control (Butler, 2005).
Several proteins are also targets of the biotechnology industry
due to their large commercial interest. In this context, the caterpil-
lar Lonomia obliqua gained great prominence in biotechnology in
Brazil, owing to the active properties identiﬁed in its venom and
in its hemolymph (Veiga et al., 2005), which can interfere in blood
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growth (Maranga et al., 2003), act as anti-apoptotic agent (Souza
et al., 2005) improve recombinant protein production (Mendonca
et al., 2009, 2008; Vieira et al., 2010) and demonstrate antiviral
effect (Greco et al., 2009).
The present study describes a system for the protein expression
in Sf9/baculovirus cells using the recombinant DNA to obtain a
protein from the L. obliqua caterpillar that displays a potent antivi-
ral action (Greco et al., 2009). This protein is found in the hemo-
lymph of L. obliqua caterpillars, and its encoding cDNA sequence
is the basic element for the construction of the expression system.
The large protein expression allows the analysis of its function and
biochemical characterization. This is the preliminary description of
the baculovirus/Sf9 cell system used for the expression of this
antiviral protein from the hemolymph of L. obliqua caterpillar.2. Materials and methods
2.1. Determination of protein and cDNA sequences and construction of
the recombinant protein
2.1.1. Sequence determination and primer design
The design of primers speciﬁc for the ampliﬁcation of the cDNA
coding for the putative antiviral protein was based on the protein
and cDNA sequences. For identiﬁcation of the protein sequence,
L. obliqua hemolymph was puriﬁed and the fraction containing
the antiviral property was analyzed by SDS–PAGE; the N-terminal
sequence of the antiviral protein was determined by Maldi-Q-Tof
mass spectrometry (Wattenberg et al., 2002). In order to identify
the cDNA coding for the protein of interest, the N-terminal se-
quence was analyzed against cDNA libraries of L. obliqua tegument
and spicules (Veiga et al., 2005), using all possible translation
frames of each cDNA. The sequence of the respective cDNA was
used for primer design and further cDNA ampliﬁcation by PCR.
Restriction sites were also included in the primer sequence for
further ligation in the plasmid pFastBac1™ (Invitrogen), as well
as a His-tag sequence.
Antiviral response of the baculovirus has been reported in the
literature (Gronowski et al., 1999) and the histidine tag can stimu-
late the immune system response (Masek et al., 2011). Therefore,
we also ampliﬁed and cloned sequences of two other proteins
(LOH-19-AY829833 and 8-LOH) that have molecular weights sim-
ilar to the protein with the histidine sequence, to conﬁrm that the
protective effects observed in the results would be due to the
action of the antiviral protein from L. obliqua (20-LOH-JN807330)
and not a response of the immune system to the His-tag sequence
(Masek et al., 2011; Veiga et al., 2005).2.1.2. RNA extraction and RT-PCR
A L. obliqua caterpillar specimen was cross-sectioned in the
middle, the extremities were cut off and RNA was extracted from
the remaining portion with Trizol (Invitrogen) according to the
Manufacturer’s instructions. The RNA was stored at 80 C until
use.
The ﬁrst-strand cDNA was synthesized using Oligo(dT)18 Primer
(Fermentas) and Superscript III reverse transcriptase (Invitrogen).
For ampliﬁcation of the sequence of interest, PCRs consisting of
12.5 ll PCR Master Mix (Promega), 200 ng of cDNA and 10 lM of
each speciﬁc primer were carried out in a thermocycler under
the following reaction conditions: initial cycle at 94 C for 3 min;
35 cycles at 94 C for 1 min and 30 s, a temperature gradient rang-
ing from 45 C to 55 C for 1 min and 30 s, and 72 C for 1 min and
30 s; ﬁnal extension at 72 C for 10 min.
Ampliﬁcation products were analyzed by electrophoresis in 1%
agarose gel containing ethidium bromide (1 lg/ml).2.1.3. Cloning in pFastBac1
The pFastBac1™ donor vector (Invitrogen™) was used in a ﬁrst
cloning step. For cloning reactions, both the vector and the
ampliﬁed cDNAs were digested with BamHI and HindIII restriction
enzymes.
After overnight incubation at 16 C, the ligation reaction was
employed in the transformation of E. coli DH5a (Invitrogen™).
Bacteria were grown on plates containing LB medium and ampicil-
lin (100 lg/ml).
Twenty colonies were selected for growth in liquid Luria–
Bertani (LB) containing ampicillin (100 lg/ml). For selection of
colonies containing the recombinant donor plasmid, cultures were
analyzed by PCR using the primers speciﬁc for the cDNA of the
antiviral protein and other proteins. Agarose gel electrophoresis
(1%) was performed to verify the ampliﬁed products.
To conﬁrm that the insert was appropriately ligated into the
cloning vector, clones screened by PCR and restriction enzyme
digestion were also subjected to sequence analyses with primers
Seq Forward pFastBac1TM (50-AAATGATAACCATCTCGC-30) and
Seq Reverse pFastBac1TM (50-CAAGCAGTGATCAGATCCAGACAT-
30). The cycle sequencing reactions were performed using the
BigDye Terminator v3.1 Cycle Sequencing Kit (code 4337456,
Applied Biosystems). Capillary electrophoresis and sequence
analyses were performed in an ABI 3730 DNA Analyzer (Applied
Biosystems), using 36 cm capillaries loaded with the POP7polymer.
Sequences were analyzed in the Sequencing Analysis 5.3.1
software.
2.1.4. Recombinant bacmid
After the generation of the pFastBac1™ construct (with the
cDNA of the antiviral protein and of the other proteins), the
puriﬁed plasmid DNAs were transformed into DH10Bac™ E. coli
for transposition into the bacmid. Identiﬁcation of the colonies
containing the recombinant bacmid was based on blue/white
colony selection.
2.1.5. Isolation and analysis of the recombinant bacmid
Extraction of bacmids was performed according to the Manu-
facturer’s protocol (Bac-to-Bac Baculovirus Expression System,
Invitrogen). To verify the presence of the gene of interest after
transposition, PCRs with M13 primers were used. The obtained
amplicons were further sequenced using the pFastBac1™ primers
for conﬁrmation of the presence of the gene of interest in the
bacmid after transposition.
2.1.6. Transfection of insect cells
Transfection of insect cells with the recombinant bacmid was
performed according to the Bac-to-Bac Baculovirus Expression
System manual (Invitrogen™). Sf9 cells in the log phase (1.5–
2.5  106 cells/ml, greater than 95% viability) were used in the
experiment, using 500 ng of the recombinant baculovirus for trans-
fection. Cell morphology was observed daily post infection for
signs of viral infection. After 144 h, the supernatant was collected
and considered as the ﬁrst passage of the recombinant baculovirus.
To conﬁrm the nucleotide sequence of the recombinant protein,
a sample from a culture infected with a second pass was collected
after 72 h. After extraction of DNA and RNA, PCR and RT-PCR were
carried out respectively, as previously indicated.
DNA samples resulting from the PCR were subjected to nucleo-
tide sequencing with the forward and reverse primers used for the
ampliﬁcation of the cDNAs.
The supernatant of all crops was collected daily for the determi-
nation of cell number, nutrient, titration of baculovirus and recom-
binant protein identiﬁcation (data not shown). Western blot with
anti-His antibody (GE Healthcare) and studies of cell morphology
with photomicrographs were performed after each step.
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2.2.1. L929 cell cultures
L929 cells were grown in plastic T-ﬂasks or on multiwell plates
using Leibovitz-15 (L15) medium containing 0.9 g L1 of D-galact-
ose, 0.3 g L1 of L-glutamine and supplemented with 5% fetal
bovine serum (FBS). Viable cell counts were performed on
Neubauer chambers using the Trypan blue (0.05%) exclusion
method.
2.2.2. Determination of the virus infectious dose
In order to determine the amount of virus produced in cultures
infected with the EMC virus that can be blocked by the antiviral
recombinant protein (rAVLO), L929was treated or not treated with
1% v/v of rAVLO, 1 h prior to culture infection. Then, cells were
infected with the EMC virus at different dilutions (rates of 10).
The microwell plates containing EMC-infected cells were then
incubated at 37 C for 3 days as described by Grifﬁths and Thorn-
ton (1982). The titers of virus produced in infected cells (treated
or not treated with rAVLO) were determined by monitoring the
cytopathic effect (CPE) in an endpoint dilution assay and the results
were expressed as the highest dilution of virus able to induce CPE
in 50% of cells.
3. Results
The protein responsible for the antiviral effect of L. obliqua
hemolymph was isolated and puriﬁed by gel ﬁltration chromatog-
raphy using a Superdex 75 column (Greco et al., 2009). Then, the
semi-puriﬁed fraction containing the antiviral activity was applied
onto an ion-exchange Resource-Q column. As previously demon-
strated by our group (Greco et al., 2009), the antiviral protein
puriﬁed by this procedure decreased the production of measles
virus (from 3.3 ± 1.25  107 to 2.1 ± 1.5  105 TCID50/ml) by 157
times the production of poliovirus (2.8 ± 1.08  109 to 4.58 ±
1.42  107 TCID50/ml) by 61 times. These differences were signiﬁ-
cant at p < 0.05. The mass spectrometry was used to determine
the N-terminal of the protein. Further, the N-terminal sequence
was analyzed against previously constructed L. obliqua cDNA
libraries (Veiga et al., 2005).
3.1. Generation of sequences of proteins of interest
RNA was extracted and the cDNA was generated as described in
Section 2. The samples were analyzed on 1% agarose gels, in which
a band of 587 bp was observed, conﬁrming the ampliﬁcation of the
cDNA that codes for the antiviral protein (Fig. 1A). The sequences
of the cDNA coding for the other proteins (LOH-19-AY829833,Fig. 1. (A) Agarose gel electrophoresis (1%) conﬁrming ampliﬁcation of the cDNA that
conﬁrming ampliﬁcation of the cDNA that codes for other proteins (line 7 for 8-LOH an
Biolabs).663 pb, and 8-LOH, 963 pb) were also conﬁrmed by agarose gel
electrophoresis (Fig. 1B).
3.2. Cloning in pFastBac1™
The ampliﬁed cDNA coding for the antiviral protein was cloned
in the pFASTBac1™ donor plasmid. As observed by agarose gel
electrophoresis in Fig. 1A, the cloned cDNA had an expected size
of 587 bp for the antiviral protein, 663 bp for LOH-19-AY829833
and 963 bp for 8-LOH (Fig. 1B).
E. coli DH5a cells were transformed to the recombinant donor
plasmid, plasmid-containing colonies were selected and the puri-
ﬁed plasmid was subsequently used in the transformation of
E. coli DH10Bac™ for the construction of the recombinant bacmids.
These bacmids, containing the sequence of a protein with antiviral
activity and other proteins, were further used for the expression of
this protein in the baculovirus/Sf9 cells system (as shown below).
3.3. Generation of the recombinant bacmid
After bacterial transformation with the recombinant plasmids
rAVLO-pFastBac1™, LOH-19-pFastBac1™ and 8-LOH-pFastBac1™,
white and blue colonies were observed in the plates. White colo-
nies were indicative that successful transposition occurred, while
blue colonies indicated that the bacmid remained unchanged.
3.4. Conﬁrmation of the recombinant bacmid
Colonies with recombinant bacmids were analyzed by PCR fol-
lowed by 1% agarose gel electrophoresis, in which baculovirus
transposition was conﬁrmed by the appearance of DNA bands
2887 for antiviral protein (Fig. 2), 2963 for LOH-19 protein and
3263 for 8-LOH protein (data not shown).
3.5. Transfection of insect cells
The recombinant plasmids were selected in E. coli DH5a and
subsequently used in the transformation of E. coli DH10Bac for
the construction of recombinant bacmids. These bacmids, contain-
ing the sequence of the protein with antiviral activity and other
chosen proteins, were used for the expression of the proteins in a
baculovirus/Sf9 cells system. Three passages of the recombinant
virus were performed in Sf9 cell cultures so far. At the moment,
titers of the baculovirus obtained in the different passages as well
as the antiviral activity of the recombinant protein produced in this
system were determined.
To eliminate the possibility that the observed effect is due to
characteristics of the construct other than the antiviral activitycodes for the antiviral protein (line 2 and 3). (B) Agarose gel electrophoresis (1%)
d line 9 for LOH-19-AY829833), M: molecular marker (1 kb Ladder, New England
Fig. 2. Agarose gel electrophoresis (1%) conﬁrming baculovirus transposition with
ampliﬁcation of the respective products. (Line 1 M: molecular marker (1 kb Ladder,
New England BioLabs), line 2 baculovirus without transposition, line 3 and 4 rAVLO
2300 bp + 591 bp protein = 2891 bp and line 5 ampliﬁcation of sequence of rAVLO
with ampliﬁcation primers.)
Table 1
Production of the picornavirus (EMC), in L929 cell cultures treated or not treated with
whole hemolymph (1%), whole or puriﬁed antiviral recombinant protein (rAVLO) or
other baculovirus recombinant protein (Rec 8-LOH). The cells were treated 1 h before
infection. The virus titers are expressed as CCID50/ml.
Poliovirus titers 72 h after infection
(TCID50/ml)
Reduction
Control infected
culture
3.1  109 ± 1.3  109
Hb 3.4  107 ± 2.1  108a 91
rAVLO (whole) 2.9  106 ± 3.63  105a 1069
rAVLO (puriﬁed) 3.2  105 ± 3.56  104a 9687
Rec 8-LOH 4.3  109 ± 1.14  109
CCID50: cell culture infectious dose 50%.
The values represent the average of three experiments.
a Indicates values at p < 0.05.
Fig. 3. Western blot of samples of a portion of AKTA (ion exchange) showing the
presence of the antiviral protein. The proteins present in the nitrocellulose
membrane were revealed with an antibody anti histidine. rAVLO: recombinant
protein with antiviral activity, negative control and positive control.
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recombinant bacmids expressing other L. obliqua proteins, namely
LOH-19 and 8-LOH (Veiga et al., 2005). These two recombinant
bacmids, as well as an empty bacmid were used to treat Sf-9 cells
infected with a picornavirus. The results showed that the empty
bacmid or those expressing the other recombinant proteins were
not effective in inhibiting the replication of EMC virus, presenting
results similar to those of the control of infected cells and of the
untreated cells. On the other hand, when infected cultures were
treated with the recombinant antiviral, there was a reduction of
about 3 logs in the viral titers in comparison to that of controls.
Therefore, when the puriﬁed antiviral protein was used, the
reduction in virus produced was around 4 logs, showing that the
recombinant antiviral protein remained fully active (Table 1). We
are currently testing the effect of the antiviral puriﬁed recombi-
nant protein on enveloped viruses (measles, rubella and herpes
simplex). Preliminary data have shown that the puriﬁed recombi-
nant protein is able to reduce by at least 4 logs the replication of
the rubella virus and by about 6 logs the replication of the herpes
simplex virus (data not shown).
To facilitate puriﬁcation, a His-tag sequence was included in the
C-terminal region of the proteins rAVLO, LOH-19-AY829833 and
8-LOH. The protein was separated by SDS–PAGE and transferred
to nitrocellulose membranes (Sambrook and Russell, 2001). After
transfer, the membrane was marked with the anti-histidine anti-
body to conﬁrm the presence of the protein. The result is shown
in Fig. 3. As can be seen, there was the presence of a band with
strong labeling with the antibody, demonstrating the expression
of the antiviral protein.4. Discussion
Viral diseases affect hundreds of millions of people worldwide
every year. Even though some antiviral drugs are under clinicaltrials, 50% of them are directed toward the treatment of HIV.
Therefore, there is a need for the development of antiviral agents
speciﬁc for emerging newly-recognized human pathogens (such
as SARS coronavirus and inﬂuenza viruses H5N1 and H1N1)
(Delcroix and Riley, 2011). Recently, various studies have reported
the antiviral properties in products obtained from arthropods.
Popham et al. (2004) have reported signiﬁcant reduction in the
titers of the baculovirus HzSNPV due to the action of an antiviral
protein present in the hemolymph of H. virescens larvae. Chernysh
et al. (2002) have isolated two peptides, alloferon 1 and 2, from the
hemolymph of Calliphora vicina, which control viral infection when
added before infection. Olicard et al. (2005) observed that the
addition of the hemolymph of Crassostrea gigas to VERO cell
cultures inhibits HSV-1. Extracts of crustacean tissues have also
shown a broad spectrum antiviral activity against enveloped and
non-enveloped DNA and RNA viruses, probably through multiple
inhibitors contained in the extracts (Pan et al., 2000). Hultmark
et al. (1980) have reported some antimicrobial properties of a
protein of 15 kDa isolated from Hyalophora cecropia caterpillars.
Alloferon, a 12.65 kDa protein puriﬁed from the hemolymph of
the ﬂy C. vicina, effectively inhibited the reproduction of inﬂuenza
A and B viruses by triggering intracellular responses when added
before virus infection similar to the interferons of vertebrates
(Chernysh et al., 2002). An antiviral peptide of 916 Da, isolated
from H. virescens hemolymph, provided protection against virus
infection (Ourth, 2004). Recently, our group has puriﬁed an
antiviral protein of approximately 20 kDa from the hemolymph
of L. obliqua; when added to cultures 1 h before infection, this
protein was able to inhibit the replication of all viruses tested in
the respective study (Greco et al., 2009).
In the present study, we cloned and expressed a recombinant
antiviral protein of L. obliqua caterpillar, named rAVLO. Further-
more, our results conﬁrmed that the recombinant protein
displayed the antiviral effect observed in the native protein present
in the hemolymph. As a matter of fact, the recombinant protein
was able to inhibit the replication of picornavirus. It was also
observed that the hemolymph did not display any virucidal effect,
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similar to alloferon, or on the late stages of virus infection, as
demonstrated by Popham et al. (2004) with a peptide extracted
from H. virescens.
In this study, the antiviral activity of L. obliqua hemolymph
against human viruses was determined in vitro and the protein
was characterized by mass spectrometry. The protocols used for
the ampliﬁcation of the cDNA of the proteins and its cloning in
pFastBac1™ were shown to be efﬁcient. The obtained bacmids,
containing the sequence of a protein with antiviral activity, were
used for the expression of this protein in Sf9 cell cultures. As
shown, rAVLO was able to block the replication of the encephalo-
myocarditis virus, a non-enveloped virus, indicating that rAVLO
kept the antiviral activity of the native protein from the hemo-
lymph. Based on these results, we propose that a protein present
in the hemolymph of the caterpillar L. obliqua displays the antiviral
activity and plays a putative role in insect immunity. Studies on the
activity of the recombinant protein with enveloped virus (rubella
virus, herpes simplex virus and measles virus) were performed.
In this case, the virus replication was inhibited by about 4 logs
for the rubella virus and about 6 logs for the herpes simplex virus
(data not shown).
The production of this protein is being optimizing both in Sf9
and in UFLAG insect cells; we are also determining the stability
of rAVLO, as well as deﬁning the effective dose of the protein.
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